Extended-spectrum β-lactamase-producing Enterobacteriaceae in an Italian Intensive Care Unit:: Clinical and therapeutical remarks

被引:6
作者
Carretto, E
Emmi, V
Barbarini, D
Marzani, FC
Bolongaro, A
Braschi, A
Marone, P
机构
[1] Univ Messina, Area Infettivol, Lab Sperimentali Ric, I-98100 Messina, Italy
[2] Univ Messina, Ist Anestesia & Rianimaz, I-98100 Messina, Italy
[3] IRCCS Policlin San Matteo, Serv Anestesia & Rianimaz 1, Pavia, Italy
[4] Univ Pavia, Cattedra Anestesiol & Rianimaz, I-27100 Pavia, Italy
关键词
ESBL; Enterobacteriaceae; epidemiology; Intensive Care Unit; Proteus mirabilis; extended spectrum beta-lactamases;
D O I
10.1179/joc.2004.16.2.145
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this study we evaluated the prevalence of Enterobacteriaceae and the epidemiology of ESBL+microorganisms in an ICU of our Institution over a 5-year period and analyzed the clinical features and outcomes of the infections caused by these microorganisms. The most frequent ESBL+ isolate was Proteus mirabilis (69 isolates, 58%); a high rate of positive results in the double-disk synergy test (DDS) was also recognized for Klebsiella pneumoniae (52 isolates, 51%), whereas this phenomenon was observed less frequently in other species. In 312 cases the isolated microorganism was considered to be the cause of infection; we documented 103 wound infections, 89 UTIs, 62 LRTIs, 30 primary bacteremias, 27 infections of indwelling catheters and 1 CNS infection. The overall mortality rate due to ESBL+ strains was 1%, compared with 10.6% rate caused by ESBL-negative Enterobacteriaceae. This could be explained because ESBL+ strains caused mostly localized infections (wound infections and UTIs), whereas systemic or severe infections were sustained by ESBL-negative strains, and therapy with carbapenems was started promptly after ESBL+ isolation (always within 24h after strain isolation).
引用
收藏
页码:145 / 150
页数:6
相关论文
共 29 条
[2]   Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998 [J].
Babini, GS ;
Livermore, DM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (02) :183-189
[3]   Prevalence of extended spectrum β-lactamases among Enterobacteriaceae:: an Italian survey [J].
Bonfiglio, G ;
Perilli, M ;
Stefani, S ;
Amicosante, G ;
Nicoletti, G .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (03) :213-217
[4]   Extended-spectrum β-lactamases in the 21st century:: Characterization, epidemiology, and detection of this important resistance threat [J].
Bradford, PA .
CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (04) :933-951
[5]   Long-term investigation of the clonal dissemination of Klebsiella pneumoniae isolates producing extended-spectrum β-lactamases in a university hospital [J].
Branger, C ;
Lesimple, AL ;
Bruneau, B ;
Berry, P ;
Lambert-Zechovsky, N .
JOURNAL OF MEDICAL MICROBIOLOGY, 1998, 47 (03) :201-209
[6]   A FUNCTIONAL CLASSIFICATION SCHEME FOR BETA-LACTAMASES AND ITS CORRELATION WITH MOLECULAR-STRUCTURE [J].
BUSH, K ;
JACOBY, GA ;
MEDEIROS, AA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) :1211-1233
[7]   Clinical relevance of Proteus mirabilis in hospital patients:: a two year survey [J].
de Champs, C ;
Bonnet, R ;
Sirot, D ;
Chanal, C ;
Sirot, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (04) :537-539
[8]   Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection:: risk factors and clinical outcome [J].
Du, B ;
Long, Y ;
Liu, HZ ;
Chen, DC ;
Liu, DW ;
Xu, YC ;
Xie, XL .
INTENSIVE CARE MEDICINE, 2002, 28 (12) :1718-1723
[9]  
Emori TG, 1998, INFECT CONT HOSP EP, V19, P308
[10]   Laboratory detection of extended-spectrum β-lactamases (ESBLs) -: The need for a reliable, reproducible method [J].
Essack, SY .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 37 (04) :293-295